# US 2020/0390870 A1 · Humanized anti-muc1* antibodies and direct use of cleavage enzyme

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390870 A1
- Document ID: US20200390870A1
- Status: Published application
- Kind: A1
- Application number: 16/767,357
- Filed: 2018-11-27
- Published: 2020-12-17
- Earliest claimed: 2017-11-27
- Assignees: Minerva Biotechnologies Corporation
- Applicants: Minerva Biotechnologies Corporation
- Inventors: Cynthia BAMDAD
- Web page: https://patentgrep.com/patent/US20200390870A1

## CPC

- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0011: {Cancer antigens}
- A61K 39/00117: {Mucins, e.g. MUC-1}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4257: {Mucins, e.g. MUC-1}
- A61P 35/00: Antineoplastic agents
- C07K 14/5418: {IL-7}
- C07K 14/5434: {IL-12}
- C07K 14/5443: {IL-15}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/3092: {against tumour-associated mucins}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12Y 304/24: Metalloendopeptidases (3.4.24)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present application discloses humanized antibodies and antibody like proteins and fragments thereof and the use of proteolytic cleavage enzymes.

## Claims

### Claim 1

A method for treating a patient diagnosed with cancer comprising administering directly to the patient, a MUC1 cleavage enzyme, alone or concurrent with an agent for treating cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent is a chemotherapy agent, targeted biological, CAR T cell, BiTE or antibody drug conjugate (ADC).

### Claim 3 (depends on 1)

The method of claim 1, wherein the cleavage enzyme is MMP1, MMP2, MMP3, MMPI, MMP8, MMP9, MMP11, MMP12, MMP13, MMP14, MMP16, ADAMS, ADAM10, ADAM17, ADAM 19, ADAMTS16, ADAM28 or a catalytically active fragment thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cleavage enzyme is MMP9 or MMP14.

### Claim 5 (depends on 2)

The method of claim 2, wherein the agent is an anti-MUC1* CAR T cell.

### Claim 6 (depends on 2)

The method of claim 2, wherein in the CAR, the single chain antibody fragment binds to a peptide comprising at least 12 contiguous amino acids of
(i) PSMGFR region of MUC1,
(ii) PSMGFR peptide,
(iii) a peptide having amino acid sequence SNIKFRPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRY (SEQ ID NO:620);
(iv) a peptide having amino acid sequence of SVVVQLTLAFREGTINVHDVETQFNQYKTEAASRY (SEQ ID NO:621);
(v) a peptide having amino acid sequence of VQLTLAFREGTINVHDVETQFNQY (SEQ ID NO:622); or
(vi) a peptide having amino acid sequence of SNIKFRPGSVVVQLTLAFREGTIN (SEQ ID NO:623).

### Claim 7 (depends on 6)

The method of claim 6, comprising portions of any of the variable regions set forth in the following:
(i) an anti-MUC1* extracellular domain antibody comprised of sequences of a humanized MN-E6 represented by humanized IgG2 heavy chain, or humanized IgG1 heavy chain, paired with humanized Kappa light chain, or humanized Lambda light chain;
(ii) an antibody of (i), wherein the humanized IgG2 heavy chain is SEQ ID NOS:53, humanized IgG1 heavy chain is SEQ ID NO:57, humanized Kappa light chain is SEQ ID NO:108, and humanized Lambda light chain is SEQ ID NO:112, or a sequence having 90%, 95% or 98% sequence identity thereof;
(iii) an anti-MUC1* extracellular domain antibody comprised of sequences of a humanized MN-C2 represented by humanized IgG1 heavy chain, humanized IgG2 heavy chain, paired with humanized Lambda light chain, and humanized Kappa light chain;
(iv) an antibody of (iii), wherein the humanized IgG1 heavy chain MN-C2 (SEQ ID NOS:159) or IgG2 heavy chain (SEQ ID NOS:164) paired with Lambda light chain (SEQ ID NO:219) or Kappa light chain (SEQ ID NO:213), or a sequence having 90%, 95% or 98% sequence identity thereof;
(v) an anti-MUC1* extracellular domain antibody comprised of sequences of a humanized MN-C3 represented by humanized IgG1 heavy chain or humanized IgG2 heavy chain paired with humanized Lambda light chain or humanized Kappa light chain;
(vi) an antibody of (v), wherein the humanized MN-C3 IgG1 heavy chain is SEQ ID NOS:454, IgG2 heavy chain is SEQ ID NOS:456, Lambda light chain is SEQ ID NO:501, and Kappa light chain is SEQ ID NO:503, or a sequence having 90%, 95% or 98% sequence identity thereof;
(vii) an anti-MUC1* extracellular domain antibody comprised of sequences of a humanized MN-C8 represented by humanized IgG1 heavy chain or humanized IgG2 heavy chain paired with humanized Lambda light chain or humanized Kappa light chain;
(viii) an antibody of (vii), wherein the humanized MN-C8 IgG1 heavy chain is SEQ ID NOS:540, IgG2 heavy chain is SEQ ID NOS:542, Lambda light chain is SEQ ID NO:580 and Kappa light chain is SEQ ID NO:582, or a sequence having 90%, 95% or 98% sequence identity thereof; or a combination thereof in the extracellular domain, a transmembrane region and a cytoplasmic tail that comprises sequence motifs that signal immune system activation.

### Claim 8 (depends on 2)

The method of claim 2, wherein in the CAR, the extracellular domain is comprised of humanized single chain antibody fragments of an MN-E6 scFv, MN-C2 scFv, MN-C3 scFv or MN-C8 scFv.

### Claim 9 (depends on 8)

The method of claim 8, in which the extracellular domain is comprised of humanized single chain antibody fragments of an MN-E6 scFv set forth as SEQ ID NOS: 233, 235, or 237), MN-C2 scFv (SEQ ID NOS:239, 241, or 243), MN-C3 scFv (SEQ ID NOS: 245, 247, or 249) or MN-C8 scFv (SEQ ID NOS:251, 253, or 255).

### Claim 10 (depends on 2)

The method of claim 2, wherein in the CAR, the cytoplasmic tail is comprised of one or more of signaling sequence motifs CD3-zeta, CD27, CD28, 4-1BB, OX40, CD30, CD40, ICAm-1, LFA-1, ICOS, CD2, CD5, or CD7.

### Claim 11 (depends on 2)

The method of claim 2, wherein in the CAR, its sequence is CARMN-E6 CD3z (SEQ ID NOS:295), CARMN-E6 CD28/CD3z (SEQ ID NOS:298); CARMN-E6 4-1BB/CD3z (SEQ ID NOS:301); CARMN-E6 OX40/CD3z (SEQ ID NOS:617); CARMN-E6 CD28/4-1BB/CD3z (SEQ ID NOS:304); CARMN-E6 CD28/OX40/CD3z (SEQ ID NOS:619); CAR-MN-E6 Fc/4-1BB/CD3z (SEQ ID NOS:311), CAR-MN-E6 IgD/Fc/4-1BB/CD3z (SEQ ID NOS:771), CAR-MN-E6 FcH/4-1BB/CD3z (SEQ ID NOS:316), CAR-MN-E6 IgD/FcH/4-1BB/CD3z (SEQ ID NOS:773), CAR-MN-E6 IgD/4-1BB/CD3z (SEQ ID NOS:324), CAR-MN-E6 X4/4-1BB/CD3z (SEQ ID NOS:331), CAR MN-C2 CD3z (SEQ ID NOS:607); CAR MN-C2 CD28/CD3z (SEQ ID NOS:609); CAR MN-C2 4-1BB/CD3z (SEQ ID NOS:611); CAR MN-C2 OX40/CD3z (SEQ ID NOS:613); CAR MN-C2 CD28/4-1BB/CD3z (SEQ ID NOS:307); CAR MN-C2 CD28/OX40/CD3z (SEQ ID NOS:615), CAR44 huMNC2-CD8-4-1BB-CD3z (SEQ ID NOS:719), CAR-MN-C2 Fc/4-1BB/CD3z (SEQ ID NOS:733), CAR-MN-C2 IgD/Fc/4-1BB/CD3z (SEQ ID NOS:735), CAR-MN-C2 FcH/4-1BB/CD3z (SEQ ID NOS:737), CAR-MN-C2 IgD/FcH/4-1BB/CD3z (SEQ ID NOS:739), CAR-MN-C2 IgD/4-1BB/CD3z (SEQ ID NOS:741), CAR-MN-C2 X4/4-1BB/CD3z (SEQ ID NOS:743).

### Claim 12 (depends on 2)

The method of claim 2, comprising a cell comprising a CAR with an extracellular domain that binds to MUC1* transfected or transduced cell.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cell comprising the CAR is immune system cell.

### Claim 14 (depends on 13)

The method of claim 13, wherein the immune system cell comprises T cell, NK cell, dendritic cell or mast cell.

### Claim 15 (depends on 2)

The method of claim 2, wherein the agent is an anti-MUC16 CAR T cell.

### Claim 16 (depends on 2)

The method of claim 2, comprising a cell with at least two CARs with different extracellular domain units transfected into the same cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein one of the extracellular domain recognition units binds to MUC1* extracellular domain.

### Claim 18 (depends on 16)

The method of claim 16, wherein one of the extracellular domain recognition units binds PD-1.

### Claim 19 (depends on 16)

The method of claim 16, wherein one of the extracellular domain recognition units is an antibody fragment and the other is a peptide or an anti-MUC1* antibody fragment.

### Claim 20 (depends on 2)

The method of claim 2, comprising an immune cell transfected or transduced with a plasmid encoding a CAR and a plasmid encoding a non-CAR species that is expressed from an inducible promoter.

### Claim 21 (depends on 20)

The method of claim 20, wherein the non-CAR species is expressed from an inducible promoter that is activated by elements of an activated immune cell.

### Claim 22 (depends on 20)

The method of claim 20, wherein the non-CAR species is expressed from an NFAT inducible promoter.

### Claim 23 (depends on 22)

The method of claim 22, wherein the NFAT is NFATc1, NFATc3 or NFATc2.

### Claim 24 (depends on 20)

The method of claim 20, wherein the cleavage enzyme is MMP2, MMP3, MMP9, MMP13, MMP14, MMP16, ADAM10, ADAM17, or ADAM28, or a catalytically active fragment thereof.

### Claim 25 (depends on 20)

The method of claim 20, wherein the non-CAR species is a cytokine.

### Claim 26 (depends on 25)

The method of claim 25, wherein the cytokine is IL-7, IL-12, IL-15 or IL-18.
